Index

abscence seizures, 152–3
academic testing
neuropsychological tests, 218
acetylcholine receptors (CHRNA4, CHRNA7)
ADHD association studies, 182
Achenbach System of Empirically Based Assessment (ASEBA), 234
Ackerman, Peggy, 7–8
acupuncture, 313
Adaptive Behavior Assessment System – II, 42
adaptivelifeskillsconcept, 42
Adderall XR®, 89, 372
ADHD (attention-deficit hyperactivity disorder)
growth of scientific awareness of, 1–2
in DSM-III-R, 16
ADHD Impact Factor, 42
ADHD Impact Module, 237
ADHD Impact Module for Adults (AIM-A), 229–30
ADHD Rating Scale (ADHD-RS), 29, 234, 276, 303
ADHD Rating Scale IV, Investigator Administered and Scored
(ADHD-IV), 228
ADHD Rating Scale IV (ADHD-RS-IV), 19, 234, 368
ADHD Symptom Checklist, 234
adolescent ADHD
assessment issues, 238–9
changing symptoms with age, 354
diagnostic evaluation components, 233
high-risk behaviors, 19
impairments associated with, 25–6
interventions, 354
predictors of persistence into adulthood, 30–1
prevalence, 24–5
recommendations for use of rating scales, 240
sociodemographic correlates, 27
adrenoleukodystrophy, 156
adult ADHD
approach to pharmacotherapy, 276
appropriateness of current diagnostic criteria, 29
comorbid psychiatric disorders, 31–2
comorbidity rates and types, 65–6
cooperating strategies, 21
depressive symptoms, 20
developmental appropriateness of diagnostic symptoms, 54–6
diagnosis, 19–20
diagnostic challenges, 11
diagnostic guidelines, 276
diagnostic scales, 224–8
differential diagnosis of adult presentation, 151–2
shortcomings of DSM-IV, 11–12
educational impairment, 20
effective interventions, 354
executive function deficits, 20
functional impairment, 20
functional impairment assessment scales, 229–30
gender differences, 19–20, 32–3
impact on interpersonal relationships, 33
impact on socioeconomic status, 33
impairments associated with, 32
mood disorders, 20
multiple comorbidities, 102
predictors of persistence of childhood ADHD, 30–1
presenting signs, 20–1
prevalence, 16, 27–9, 83–4
quality of life assessment scales, 229–30
rates of underdiagnosis and undertreatment, 16
recognition of, 10–12
role of rating scales in diagnosis, 230
self-reported symptom scales, 228
setting treatment goals, 276
sociodemographic correlates, 32–3
subtypes, 20
symptom assessment scales, 228–9
total cost to society, 33–4
treatment comparison in various countries, 33
treatment response rating scales, 276
use of diagnostic interviews, 224
use of symptom rating scales, 224
workplace screening programs, 34
See also college students with ADHD
Adult ADHD Clinician Diagnostic Scale version 1.2 (ACDS v1.2), 29, 224–7
Adult ADHD Investigator Symptom Rating Scale (AISRS), 228, 303
Adult ADHD Quality of Life (AAQoL) scale, 229
Adult ADHD Self-Report Scale (ASRS), 118, 229, 354, 368
Adult ADHD Self-Report Scale Version 1.1 Screener, 84
Adult ADHD Symptoms Scale, 227
Adults with ADD (organization), 92
adverse events
rating scales to track, 237–8
age-of-onset diagnostic criterion problems with, 56–7
age-related changes in ADHD, 27
agoraphobia, 99
Allen, R. P., 10
alpha-adrenergic agents
use in preschool ADHD, 323
alpha-adrenergic agonists
use in adult ADHD, 289
use in tic disorders, 348
use in Tourette syndrome, 348
alpha-2 agonists
dosage and administration for ADHD, 263–5
effects on prefrontal cortical function, 167–8
use by college students with ADHD, 373
use in ODD or CD with ADHD, 146
amantadine, 261, 267
Amartruda, C. S., 7
American Academy of Child and Adolescent Psychiatry (AACAP), 18, 88, 103, 276, 321
American Academy of Pediatrics (AAP), 18, 103, 321
American Medical Association (AMA), 58
Americans with Disabilities Act (ADA), 58–9, 368
amino acid supplementation
adults, 313
children, 309
amino acid treatments, 289
ampakines, 289
amphetamine, 6, 10, 76, 118, 165, 371
effects of the FDA Modernization Act (1997), 12
use in preschool ADHD, 322–3
See also stimulant medications
amphetamine abuse, 114
amphetamine preparations, 245, 246–7
pharmacokinetics, 247
anticoagulants, 248
anticonvulsants, 283
antidepressants
risk of suicidality, 147
use in adult ADHD, 288–9
use in comorbid depression and ADHD, 90–1
use in ODD or CD with ADHD, 147
See also specific categories and specific antidepressants
antihistamines, 282
antipsychotic medications
use in ODD or CD with ADHD, 147
antisocial personality disorder, 144, 145, 148
Antisocial Process Screening Device, 146
anxiety
in hyperactive children, 6
anxiety disorders
comorbidity with conduct disorder (CD), 144
comorbidity with ODD, 144
overlap with reverse comorbidities, 64
anxiety disorders and ADHD, 18
and oppositional defiant disorder (ODD), 102
developmental perspective, 99–100
diagnosis (case study), 220
diagnostic challenges, 101
future directions, 105–6
gender differences, 101–2
neuropsychological assessment, 213–14
prevalence in ADHD subtypes, 102
prevalence of comorbidity, 98–9
protective potential of stimulant treatment, 253–4
secondary anxiety in association with ADHD, 102
shared neurobiological and neuroendocrine features, 100–1
treatments, 103–5
Aplenzin, 265
aripiprazole, 76, 147, 349
asenapine, 147
Asperger's disorder, 213
asthma, 158
atomoxetine, 76, 77, 89, 104–5, 161, 261, 371
administration with stimulant medications, 283
adverse events, 251
dosage and administration for ADHD, 261–3
effects on prefrontal cortical function, 165–7
SUD studies, 114
use by college students with ADHD, 373
use in adult ADHD, 283–8
use in ODD or CD with ADHD, 146
use in preschool ADHD, 323
use in tic disorders and ADHD, 348
use in Tourette syndrome and ADHD, 348
attention
fMRI studies, 203–4
neuropsychological tests, 215–16
role of the prefrontal cortex, 161–2
attention deficit disorder (ADD) (DSM-III), 16
attention training, 311–12, 314
attentional deficit syndrome recognition of, 7–8
attentional performance
effects of nicotine, 333
attention-deficit hyperactivity disorder (ADHD). See ADHD
autism spectrum disorder (ASD), 60, 151, 240
attention spectrum disorder (ASD) and ADHD, 64
use of stimulant medications, 252–3
Barkley, Russell A., 11–12, 43, 46, 355–6
Barkley Adult ADHD Rating Scale–IV (BAARS-IV), 227, 229
Barkley Deficits in Executive Functioning Scale (BDEFS), 368
Barkley Functional Impairment Scale (BFIS), 59, 230
Beck Anxiety Inventory (BAI), 218
Beck Depression Inventory (BDI), 91, 299
Beck Depression Inventory – Second Edition (BDI-II), 218
Beery Tests of Developmental Visualmotor Integration, 217
Behavior Assessment Scale for Children (BASC), 240
Behavior Assessment Scale for Children – Second Edition (BASC-2), 218
Behavior Assessment System for Children, second edition, 234
behavior regulation
role of the prefrontal cortex, 161–2
behavior therapy
for tics, 349
behavioral inhibition
effects of nicotine, 333
behavioral parent training (BPT), 147–8
behavioral therapy
in multimodal therapy, 10
benzphetamine, 6
Big Data, 206
bilateral perisylvian syndrome with polymicrogyria, 151
biofeedback, 311
bipolar disorder
ADHD in patients presenting with, 85–6
comorbidity with ADHD, 66–7
differential diagnosis, 152
bipolar disorder and ADHD
age of onset of each, 73–4
assessment scales, 73
bidirectional comorbidity, 74
case study (bipolar disorder of childhood), 219
comorbid major depressive disorder (MDD), 74
comorbidity in children and adolescents, 25
diagnostic challenges, 72–3
effects of ADHD on bipolar disorder symptoms, 75
effects of mood-stabilizing agents, 76
familial risk analysis, 75
future studies, 77
guidelines for management, 76
importance of diagnosis of comorbidity, 72
lack of recognition in adults, 72
neuroimaging studies, 75–6
neuropsychological assessment, 214
overlapping symptoms, 74
prevalence of comorbidity, 74
psychopharmacological responses, 76
recognition of childhood bipolar disorder, 72
response to anti-manic treatments, 76
response to stimulants, 76–7
risk of over-diagnosis, 74
bipolar disorder and ADHD (cont.)
stimulant medications for pediatric use, 252
studies, 73
transmission of comorbid disorders in families, 75
trials of non-stimulant anti-ADHD agents, 77
blepharospasm, 343
BOLD technique, 201–2
borderline personality disorder
effects of ADHD and depression, 87
Boring, Edwin, 2, 4
Boston Naming Test-2 (BNT-2), 216
botulin toxin, 349
Bradley, Charles, 5–6, 353
brain-derived neurotrophic factor
Brown Attention Deficit Disorder
Brown Adult ADHD Rating Scale, 227
Brown Attention Deficit Disorder
Diagnostic Form, 227–8
Brown Attention Deficit Disorder
Scales (BADDs), 19, 228, 234, 299
for Adults, 228, 368
for Children and Adolescents, 239
bupropion, 77, 90, 114, 336, 373
dosage and administration for
ADHD, 265–6
use in adult ADHD, 288
Burrows, George Mann, 2–3
buspirone, 261, 266
caffeine, 282
California Verbal Learning Test-II
(CVLT-II), 217
callous-unemotional traits, 144
Campbell, Susan, 123
Canadian ADHD Resource Alliance
(CADDTA), 88
Canadian Network for Mood and
Anxiety Treatments, 76
cancer risk
and use of stimulant medications, 250–2
Cantwell, Dennis, 4
carbamazepine, 76, 147
cardiac complications risk
and use of stimulant medications, 250–1
cardiovascular system
effects of stimulant medications, 260
L-carnitine supplementation, 308–9
Castellanos, Xavier, 10
Catch-22 syndrome, 152
catechol-O-methyltransferase (COMT)
ADHD association studies, 177
catecholamine-trimaine reuptake
inhibitors, 289
catecholaminergic genes
ADHD association studies, 175–80

dose and administration for
ADHD, 263–5
effects on prefrontal cortical function, 167–8
pharmacokinetic and
pharmacodynamic properties, 263–4
treatment discontinuation, 265
use in adult ADHD, 289
use in young children, 323
clonidine extended-release (CXR), 261, 263
cognitive enhancement
effects of stimulant medications in
normal subjects, 164–5
cognitive-behavioral therapy (CBT), 91, 103, 113, 299
for college students with ADHD, 374
Mount Sinai CBT program for adult
ADHD, 300–4
range of therapeutic approaches, 374
cognitive control training. See
executive function training
cognitive training, 314
college students with ADHD
academic accommodations, 369–70
academic support, 370–1
ADHD coaching, 370–1
assessment, 367–9
functional impairments, 366–7
impacts of ADHD for young adults, 366
medication issues, 371–3
psychosocial treatments, 373–4
symptoms, 366–7
treatment options, 369–74
combined micronutrient supplement, 313
combined subtype of ADHD
(DSM-IV), 16
comorbidity in ADHD
categorical view of disorders, 64
childhood ADHD comorbidities, 25
clinical assessment, 64–5
dimensional view of disorders, 64
evolving views, 67–8
future directions, 68
importance of diagnosing
comorbidities, 63
mood dysregulation and
comorbidity, 66–7
psychiatric disorders in adult
ADHD, 31–2
psychiatric disorders in children
with ADHD, 18
rates and types in adult ADHD, 65–6
rates and types in childhood ADHD, 65
research paradigm, 63–4
reverse comorbidity, 63, 64
symmetrical and asymmetrical overlap between disorders, 64
temper dysregulation disorder (TDD), 66–7
See also specific comorbidities
complementary and alternative medicines (CAMs)
definition, 307
complementary and alternative treatments (CATs) for ADHD
amino acid supplementation (adults), 313
amino acid supplementation (children), 309
attention training, 311–12, 314
biofeedback, 311
L-carnitine supplementation, 308–9
clinical recommendations, 315
cognitive training, 314
combined micronutrient supplement, 313
definition of CATs, 307
dimethylaminoethanol (DMAE) supplementation, 309
EEG biofeedback, 311
efficacy evaluations, 307
electro-acupuncture, 313
electromyographic biofeedback (EMG-BF), 311
elimination diets, 307–8
essential fatty acid (EFA) supplementation, 308
executive function training, 311–12, 314
exercise, 313
future research, 314–15
ginkgo biloba, 310
ginseng, 310
glyconutritional supplementation, 309–10
heart-rate variability biofeedback (HRV-BF), 311
herbal interventions, 310
homeopathic remedies, 310–11
ingestible CATs for adult ADHD, 313
ingestible CATs for pediatric ADHD, 307–11
iron supplements, 309
light therapy, 314
magnesium supplements, 309
massage therapy, 312–13
meditation/mindfulness, 312
melatonin supplementation, 310
mindfulness meditation training (MMT), 314
neurofeedback, 311, 313–14
ningdong granules, 310
noningestible CATs for adult ADHD, 313–14
noningestible CATs for pediatric ADHD, 311–13
nutritional supplementation, 308–10
Pycnogenol, 310, 313
range of treatments, 307
relaxation therapies, 311
safety evaluations, 307
St. John’s wort, 310
vestibular stimulation, 312
vitamin supplementation, 309
working memory training, 311–12, 314
yoga, 312
zinc supplements, 309
comprehensive behavioral intervention for tics (CBIT), 349
coping strategies in adults with ADHD, 21
corticosteroids, 343
coproporaxia, 343
copy number variation in ADHD molecular genetics, 185
costs of ADHD
total cost of adult ADHD, 33–4
costs of childhood ADHD, 26–7
consequences of high-risk behaviors, 26
family burden, 27
healthcare services, 26–7
poor educational performance, 26
quantifying the costs, 27
Crichton, Sir Alexander, 2, 10
Daytrana, 93
Deaner®, 309
deanol, 309
default network interference hypothesis of ADHD, 203
delayed sleep phase syndrome, 155

Conners’ Adult ADHD Diagnostic Interview for DSM-IV (CAADDID), 224
Conners’ Adult ADHD Rating Scales (CAARS), 104, 228–9, 276, 368
Conners’ Adult ADHD Rating Scales (CAARS-S-I), 299
Conners’ Adult ADHD Rating Scale-Self Report (CAARS-S-S), 266
Conners’ Comprehensive Behavior Rating Scales, 234
Conners’ Continuous Performance Test, 215
Conners’ Continuous Performance Test-II (CPT-II), 125
Conners’ Early Childhood Scale, 240
Conners’ Parent Rating Scale (CPRS), 240, 319, 320
Conners’ Rating Scales, 19, 234, 319
Conners’ Rating Scales, 3rd edition (Conners 3), 218, 234
Conners’ Teacher Rating Scale (CTRS), 319, 320
Conners–Wells’ Adolescent Self-Report, 239
Continuous Performance Task (CPT), 333
Continuous Performance Test (CPT), 330
continuous performance tests, 215
Controlled Oral Word Association (COWA), 216
coping strategies in adults with ADHD, 21
coprolalia, 343
cortisol levels in ADHD patients, 157–8
costs of ADHD
total cost of adult ADHD, 33–4
costs of childhood ADHD, 26–7
consequences of high-risk behaviors, 26
family burden, 27
healthcare services, 26–7
poor educational performance, 26
quantifying the costs, 27
Crichton, Sir Alexander, 2, 10
Dandy, Walter, 5
Daytrana, 93
Deane® , 309
deanol, 309
default network interference hypothesis of ADHD, 203
 delayed sleep phase syndrome, 155

© in this web service Cambridge University Press
www.cambridge.org
Delis–Kaplan Executive Function System (D-KEFS), 216
dementia
differential diagnosis of ADHD, 156
Denhoff, Eric, 6–7, 10
deprenyl, 90, 288
depressive disorders
epidemiology, 82–3
increased risk in adults with ADHD, 82
overlap with reverse comorbidities, 64
range of disorders and etiologies, 82–3
relationship with ADHD, 83–4
depressive disorders and ADHD
ADHD in adults presenting with bipolar disorder, 85–6
ADHD in adults presenting with major depressive disorder, 85–6
association between obesity and depression, 87
borderline personality disorder, 87
clinical guidance based on type of depressive disorder, 92–3
clinical presentation in adults, 84–5
comorbid seasonal affective disorder (SAD) and ADHD in adults, 85
course of ADHD in adults, 84–5
depressive symptoms in adults with ADHD, 20
effects on personality development, 87
emotional impulsivity in adults, 86–7
emotional regulation difficulties in adults, 86–7
executive function deficits in adults, 86–7
medications, 89–91
prevalence of comorbidity, 83–4
protective potential of stimulant treatment, 253–4
psychosocial treatments and support, 91–2
recurrent brief depression (RBD) in adults with ADHD, 85
role of antidepressants, 90–1
suicide risk, 87
treatment approach for adult patients, 87–9
Treatment of Adolescent Depression (TADS) study, 89
treatments, 89–93
use of non-stimulant medications, 89–90
use of stimulant medications, 89
descriptive behavioral model of ADHD, 9–10
desipramine, 147, 267
desvenlafaxine, 261
development concept, 42
developmental dyslexia. See reading disorders
dexamfetamine, 146
dextromethorphan, 89, 245
dextroamphetamine, 103, 246
dextroamphetamine sulfate, 245
dextromethorphan, 371
diagnosis of ADHD
age-appropriateness of diagnostic thresholds, 54
appropriateness of diagnostic criteria for adults, 29
burden of undiagnosed and untreated ADHD, 16
case for inclusion of emotional criteria, 56
case for sex-referenced criteria, 56
changing presentation over time, 19
clinical relevance of ADHD subtypes, 59–60
comorbid psychiatric disorders in children, 18
coping strategies in adults, 21
cross-setting pervasiveness of symptoms, 57–8
definition of impairment, 58–9
developmental appropriateness of diagnostic symptoms, 54–6
DSM-5 diagnostic criteria, 17–18
DSM-IV-TR diagnostic criteria, 16–18
duration of current symptoms, 57
early descriptions, 9–10
history of inclusion in DSM editions, 16
in adults, 19–20
in children, 18–19
presenting signs in adults, 20–1
problems with the age-of-onset criterion, 56–7
question of minimum age for diagnosis, 57
rates of underdiagnosis and undertreatment, 16
ratings scales to aid diagnosis in children, 19
subtypes of ADHD, 16, 17
diagnosis of adolescent ADHD diagnostic evaluation components, 233
diagnosis of childhood ADHD diagnostic evaluation components, 233
Diagnostic and Statistical Manual of Mental Disorders. See DSM
Diagnostic Interview for ADHD in Adults (DIVA), 228
Diagnostic Interview for Children-IV (DISC-IV), 238
diagnostic interviews for ADHD, 238
choice of, 238
description, 238
recommendations for clinical use, 240
diagnostic scales for adult ADHD, 224–8
use in adult ADHD, 224
See also rating scales; symptom rating scales
dialectical behavior therapy (DBT), 299
differential diagnosis of ADHD
ADHD presentation in adults, 151–2
case study, 219
dementia, 156
diagnostic approach, 150
effects of illicit substances, 152
effects of medications, 152
dopamine dysregulation, 156–8
epilepsy, 152–4
genetic disorders, 152
HPA axis abnormalities, 157–8
hyperthyroidism, 157
hypothyroidism, 156–7
medical evaluation, 151–2
movement disorders, 154
neurodevelopmental disorders, 151
neurogenetic disorders, 155–6
PANDAS, 154
resistance to thyroid hormone, 157
seizure disorders, 152–4
sensory deficits, 152
sleep disorders, 154–5
Syndenham's chorea, 154
thyroid disorders, 156–7
tic disorders, 154
Tourette syndrome, 154
diffusion–tensor imaging (DTI) studies in ADHD, 200–1
dimethylaminolactic acid (DMAE)
supplementation, 309
dimethylthanolamine, 309
direct observation therapy (DOT), 357
disruptive behavior disorders (DBD)
DSM-IV criteria, 139
See also conduct disorder (CD);
oppositional defiant disorder (ODD)
divalproex sodium, 76
dopa decarboxylase (DDC)
ADHD association studies, 182
dopamine
effects on prefrontal cortical function, 162–3
dopamine beta-hydroxylase (DBH) association studies, 178
dopamine D1 receptor (DRD2) association studies, 179
dopamine D2 receptor (DRD2)
ADHD association studies, 179
dopamine D3 receptor (DRD3)
ADHD association studies, 179
dopamine D4 receptor (DRD4)
ADHD association studies, 175–7
dopamine D5 receptor (DRD5)
ADHD association studies, 177
dopaminergic mechanism for ADHD
Wender’s proposal, 8
Douglas, Virginia, 7, 123
driving, 49

drug–drug interactions, 248, 282–3

DSM
history of ADHD inclusion, 16
DSM-I
hyperkinetic behavior syndrome, 9

DSM-III
hyperkinetic behavior syndrome, 9
hyperkinetic reaction of childhood, 16

DSM-III-R
attention deficit disorder (ADD), 16
change in diagnostic approach, 9–10

DSM-IV
ADHD definition, 16
DSM-IV
age-appropriateness of ADHD diagnostic thresholds, 54
criteria for disorder of written expression, 126
criteria for learning disabilities, 125–6
criteria for mathematics disorder, 125

criteria for reading disorder, 125
cross-setting pervasiveness of ADHD symptoms, 57–8
disruptive behavior disorders (DBD), 139
problems with the age-of-onset criterion, 56–7
proposed changes to ADHD diagnostic criteria, 53–4
re-classification of ADHD symptoms, 16
shortcomings for adult ADHD, 11–12
three subtypes of ADHD, 16
DSM-IV-TR
criteria for conduct disorder (CD), 140
criteria for oppositional defiant disorder (ODD), 139–40
diagnostic criteria for ADHD, 16–18

DSM-5
addressing issues in DSM-IV, 60
age-appropriateness of diagnostic thresholds, 54
case for including sex-referenced criteria, 56
case for inclusion of emotional criteria in ADHD, 56
clinical relevance of ADHD subtypes, 59–60
cross-setting pervasiveness of ADHD symptoms, 57–8
definition of impairment, 58–9
developmental appropriateness of ADHD symptom content, 54–6
diagnostic criteria for ADHD, 17–18
diagnostic criteria for tic disorders, 344
duration of current symptoms, 57
modifications to ADHD diagnostic criteria, 368
problems with the age-of-onset criterion, 56–7
proposed changes to DSM-IV ADHD diagnostic criteria, 53–4
proposed temer dysregulation disorder (TDD), 66–7
question of minimum age for ADHD diagnosis, 57
duloxetine, 91
Dykman, Roscoe, 7–8
dyslexia. See reading disorders
echo-planar imaging (EPI), 202
echopraxia, 343
education
interventions for behavior-disordered children, 7–8
special methods for behavior-disordered children, 7
specific learning disability, 7–8
specific learning disorder, 6
educational impairment in adults with ADHD, 20
educational performance burden of childhood ADHD, 26
causes of poor educational performance, 6
effects of ADHD at different ages, 19
functional impairment in ADHD, 45–6
protective potential of stimulant treatment, 253–4
See also college students with ADHD
EEG biofeedback, 311
Eisenberg, Leon, 10
electro-acupuncture, 313
electromyographic biofeedback (EMG-BF), 311
elimination diets, 307–8
elimination disorders and ADHD, 152
emotional criteria
case for inclusion in ADHD diagnostic criteria, 56
ermal disorder (OCD), 56
emotional dysregulation in ADHD, 49
emotional function
neuropsychological tests, 217–18
emotional regulation
role of the prefrontal cortex, 161–2
employment prospects
adults with ADHD, 20

Encephalitis Lethargica pandemic, 5–6
Endicott Work Productivity Scale (EWPS), 47
endocrinopathies
differential diagnosis of ADHD, 156–8
epidemiology
age-related changes in ADHD, 27
comorbid psychiatric disorders in adult ADHD, 31–2
comorbidity with childhood ADHD, 25
gender differences in childhood ADHD, 27
prevalence of adult ADHD, 16, 27–9, 83–4
prevalence of childhood ADHD, 16, 24–5
sociodemographic correlates of adult ADHD, 32–3
sociodemographic correlates of childhood/adolescent ADHD, 27
epilepsy
differential diagnosis of ADHD, 152–4
epilepsy and ADHD
stimulant medications for pediatric use, 253
Equal Employment Opportunity Commission (EEOC), 58
essential fatty acid (EFA) supplementation, 308
etiology of behavioral problems
brain injury theories, 7–9
perinatal brain injury theories, 7–9
European Network Adult ADHD, 88, 276
executive function training, 311–12, 314

383
executive functions
deficits in ADHD, 49
deficits in adults with ADHD, 20
deficits in childhood and adolescent ADHD, 25–6
neuropsychological assessment, 212–13
neuropsychological tests, 215–16
exercise therapy, 313
externalizing disorders, 144
extra-Y syndrome, 152
Eyberg Child Behavior Inventory, 145
Facial Recognition test, 216
Fagerström Test of Nicotine Dependence, 328
Facial Recognition test, 216
Focalin XR ⃝, 372
Food and Drug Administration (FDA) Modernization Act (1997), 12
Fortivo, 265
fragile X syndrome, 152
“frontal” neuropsychological tests, 215–16
Full Scale Intelligence Quotient (FSIQ) neuropsychological assessment, 211–12
Full Scale IQ (in WISC-IV), 126
functional impairment assessment scales, 229–30
concept, 42
rating scales, 236–7
functional impairment in ADHD defining functional impairment, 42–5
educational achievement, 45–6
in adults, 20
range of potential impairments, 49–50
social functioning, 47–9
work environment, 46–7
future research in ADHD epidemiology, 34–5
GAF scale, 42
Gage, Phineas, 162
gender differences in ADHD case for sex-referenced diagnostic criteria, 56
changes over time, 19–20
comorbid anxiety disorders and ADHD, 101–2
in adults, 32–3
in childhood ADHD, 27
general intellectual skills neuropsychological assessment, 211–12
generalized anxiety disorder (GAD), 100
genetic disorders
differential diagnosis of ADHD, 152
genetic factors in ADHD and catecholamine dysregulation, 162
effects on prefrontal cortical function, 162
genetic factors in tic disorders, 347
genetic linkage studies in ADHD, 174–5
genetic theories of ADHD etiology, 8
genome-wide association studies (GWAS), 183–4
 genotype × environment interaction in ADHD, 184
German Federal Ministry of Research and Education, 299
Gesell, A., 7
ginkgo biloba, 310
ginseng, 310
Global Assessment of Functioning Scale, 59
glucocorticoid medications, 158
glutamate receptor genes
ADHD association studies, 182
glycinergic neurotransmission, 109–10
Go/No-Go task, 67, 162
Goethe, Johann Wolfgang von, 2
Gordon Diagnostic System, 215
gray matter volumes
differential diagnoses of ADHD, 200
Gray Oral Reading Test (GORT-5), 218
Great Man theory of scientific progress, 2–5
growth in children
effects of stimulant medications, 250, 259–60
guanetidine, 248
guanfacine, 146, 161, 163, 250, 261
adverse effects, 265
dosage and administration for ADHD, 263–5
effects on prefrontal cortical function, 167–8
pharmacokinetic and pharmacodynamic properties, 264–5
treatment discontinuation, 265
use in adult ADHD, 289
use in young children, 323
guanfacine extended-release (GXR), 261, 263
habit reversal training/therapy (HRT), 349
haloperidol, 349
Hamilton Depression Rating Scale, 86
healthcare services
costs related to children/adolescents with ADHD, 26–7
use by children/adolescents with ADHD, 26–7
heart-rate variability biofeedback (HRV-BF), 311
height (growth)
effects of stimulant medications, 250
herbal interventions, 310
heritability of ADHD, 174
heterotopias, 151
high-risk behaviors
burden of childhood ADHD, 26
in adolescents with ADHD, 19
higher cortical functions
neuropsychological assessment, 212–13
history of ADHD
brain damage view, 5–6
competing views, 1–2
development of multimodal therapy, 10
diagnosis of ADHD, 9–10
discovery of effects of stimulant drugs, 5–6
DSM-III, 9–10
early psychopharmacology, 5–7
etiological models, 7–9
genetic theories, 8
Great Man theory of scientific progress, 2–5
growth of scientific awareness, 1–2
hyperkinetic impulse disorder, 6–7
in editions of the DSM, 16
influence of Encephalitis Lethargica pandemic, 5–6
influence of the FDA Modernization Act (1997), 12
minimal brain dysfunction (MBD), 7–10
moral defect models, 2–5
neurological explanations, 10
NINCDS perinatal study, 9
non-scientific reasons for recent interest in ADHD, 12
organic drivenness concept, 7
overstimulation theories of disruptive behavior, 2–5, 6–7
pneumo-encephalograms (PEG), 5–6
pre-scientific origins of ADHD, 2–5
proposed dopaminergic mechanism, 8
recognition of adult ADHD, 10–12
shift towards descriptive behavioral model, 9–10
Zeitgeist explanation for scientific progress, 2–5
HIV encephalopathy, 152
Hoffman, Heinrich, 3–4
Home and School Situations Questionnaires, 145
homeopathic remedies, 310–11
Hume, David, 1
hyperkinetic behavior syndrome, 9
hyperkinetic impulse disorder, 6–7
hyperkinetic reaction of childhood (DSM-II), 16
hyperthyroidism
differential diagnosis of ADHD, 157
hypothalamic–pituitary–adrenal (HPA) axis abnormalities
differential diagnosis of ADHD, 157–8
hypothyroidism
differential diagnosis of ADHD, 156–7
ICD-10
diagnostic criteria for tic disorders, 344
imipramine, 147, 267
improvement
definition of, 58–9
Impairment Rating Scale (IRS), 237
impairments
associated with adult ADHD, 32
associated with childhood ADHD, 25–6
imprinting effects in ADHD genetics, 184
Inattentive Subtype of ADHD, 2
Indian herbal medicine, 310
Individuals with Disabilities Education Act (IDEA), 12
infrequent pandemic, 5
inhibition
fMRI studies, 203–4
intelligence
neuropsychological tests, 215
internalizing disorders, 144
International Mood Disorders Collaborative Project, 86
internet addiction, 49
interpersonal relationships
impact of adult ADHD, 33
interpersonal skills training, 148
Intuniv, 263
IQ (intelligence quotient)
neuropsychological assessment, 211–12
IQ tests, 215
iron supplements, 309
James, William, 3, 4
Jensen, Peter, 11
Judgment of Line Orientation (perceptual judgment) test, 216
Kapvay, 263
ta, 310
Kiddie Schedule for Affective Disorders and Schizophrenia (K-SADS), 66, 184, 218, 225, 238
module on ADHD, 228
Kiddie-Schedule for Affective Disorders and Schizophrenia-Epidemiological Fifth Version (K-SADS-E), 72
Klein Levinsyndrome, 155
Klein, Donald, 8
Klein, Rachel, 8
Klinefelter syndrome, 152
Kuhn, Thomas, 9
language
influence on behavior, 355–6
language abilities
neuropsychological assessment, 213
neuropsychological tests, 216
Laurier, Maurice, 6–7, 9
learning ability
neuropsychological assessment, 214
neuropsychological tests, 217
learning disability
definition, 123
educational rights, 369
etiological theories, 7–9
learning disorder
definition, 123
range of cognitive abnormalities, 123
learning disorders and ADHD
case study, 218–19
case study (mathematics disorder, mixed receptive-expressive disorder, prenatal drug addiction), 130–3
case study (reading disorder and ADHD), 127–30
diagnostic criteria for learning disabilities, 125–6
discrepancy approach to learning disorder diagnosis, 126
disorder of written expression and ADHD, 127
DSM-IV criteria for disorder of written expression, 126
DSM-IV criteria for learning disorders, 125–6
DSM-IV criteria for reading disorder, 125
educational impairment in ADHD, 123
mathematics disorder and ADHD, 127
mathematics disorder, mixed receptive-expressive disorder, prenatal drug addiction (case study), 130–3
measuring aptitude and achievement, 126
neurobiology of ADHD, 123–4
neurobiology of learning disorders, 124
prevalence of comorbidity, 123
reading disorder and ADHD, 127
reading disorder and ADHD (case study), 127–30
response to intervention model for learning disorder diagnosis, 126
studies of comorbidity, 124–5
Liebowitz Social Anxiety Scale, 104
light therapy, 314
lisdexamfetamine, 118, 246–7, 371
liothium, 76, 147
Lorenzo's disease, 156
magnesium supplements, 309
magnetic resonance imaging (MRI)
development of, 198
studies of ADHD, 10
See also neuroimaging
major depressive disorder
ADHD in patients presenting with, 85–6
major depressive disorder (MDD) and ADHD, 74
MAS (mixed amphetamine salts) formulations, 246
massage therapy, 312–13
mathematics disorder
and ADHD, 127
DSM-IV criteria, 125
Mayes, Rick, 12
Medicaid
expanded eligibility for reimbursement, 12
Medication Event Monitoring System (MEMS®), 354
medication holidays, 248
medication side effects
differential diagnosis for ADHD, 152
meditation/mindfulness, 312
melatonin supplementation, 310
memory
neuropsychological assessment, 214
neuropsychological tests, 217
metachromatic leukodystrophy, childhood onset, 156
metacognitive therapy (MCT), 91
methadone, 114
methylphenidate, 10, 76–7, 87, 104, 146, 165, 371
actions in the prefrontal cortex, 161
effects of the FDA Modernization Act (1997), 12
Preschool ADHD Treatment Study (PATS), 319–21, 322
SUD studies, 114
use in preschool ADHD, 323
See also stimulant medications
methylphenidate preparations, 245–6
pharmacokinetics, 247

Millwaukee Young Adult Outcome Study, 20
mimics of ADHD. See differential diagnosis of ADHD
mindfulness-based cognitive therapy (MBCT), 91
mindfulness meditation training (MMT), 314
Mini International Neuropsychiatric Interview (MINI version 4.4), 73
minimal brain dysfunction (MBD), 7–10
Minnesota Multiphasic Personality Inventory – 2nd Edition and Adolescent version (MMPI-2; MMPI-A), 218
moclobemide, 288
modafinil, 266–7, 289
molecular genetics of ADHD
acetylcholine receptors (CHRNA4, CHRNA7), 182
association studies of catecholaminergic genes, 175–80
association studies of serotonergic genes, 180–2
brain-derived neurotrophic factor (BDNF), 182–3
candidate gene studies, 175
catechol-O-methyltransferase (COMT), 177
copy number variation and ADHD, 185
dopa decarboxylase (DDC), 182
dopamine beta-hydroxylase (DBH), 178
dopamine D1 receptor (DRD2), 179
dopamine D1 receptor (DRD3), 179
dopamine D2 receptor (DRD4), 179–8
Dopamine D3 receptor (DRD5), 177
dopamine transporter gene (DAT1, SLC6A3), 177–8
future research, 185–6
Genetic linkage studies, 174–5
genome-wide association studies (GWAS), 183–4
Genotype × environment interaction, 184
glutamate receptors, 182
heritability of ADHD, 174
imprinting effects, 184
monoamine oxidase A (MAO-A), 178–9
monoamine oxidase B (MAO-B), 179–8
neurotrophic-3 (NTF-3), 180
nitric oxide synthase (NOS1), 183
noradrenergic receptors (ADRA1A, A2A, 2C and 1C), 179–80
norepinephrine transporter (NET, SLC6A2), 180
parent-of-origin effects, 184
search for common variants, 183–4
search for rare variants, 184, 185
serotonin receptor (HTR1B), 180–1
serotonin receptor (HTR2A, SHT2A), 181
serotonin transporter (5HTT, SLC6A4), 181
substance-prefering receptor (Tacr1), 183
synaptosomal associated protein (SNAP-25), 182
tryptophan hydroxylase (TPH and TPH2), 181–2
monoamine oxidase A (MAO-A)
ADHD association studies, 178–9
monoamine oxidase B (MAO-B)
ADHD association studies, 179
monoamine oxidase inhibitors (MAOIs), 90
drug–drug interactions, 283
use in ADHD treatment, 267
use in adult ADHD, 288–9
Montgomery–Asberg Depression Rating Scale, 86
mood disorders
comorbidity with conduct disorder, 144–5
comorbidity with ODD, 144–5
in adults with ADHD, 20
mood dysregulation associated with stimulant medications, 251
mood regulators
use is ODD or CD with ADHD, 147
moral defect models of disruptive behavior, 2–5
motor skills
neuropsychological tests, 217
Mount Sinai CBT program for adult ADHD, 300–4
movement disorders
differential diagnosis of ADHD, 154
Multidimensional Anxiety Scale for Children, Second Edition (MASC2), 218
multidimensional treatment foster care (MTFC), 148
multimodal therapy, 10
Multimodal Treatment of ADHD (MTA) study, 10, 45, 65, 103, 147, 148, 259, 260, 322, 354–5
multisystemic therapy (MST), 148
myotonic dystrophy, 155

narcolepsy, 155
National Comororbidity Survey Replication (NCS-R), 83, 225
National Initiative for Children's Healthcare Quality (NICHQ), 321
National Institute for Health and Care Excellence, 88
National Institute of Neurological and Communicative Disorders and Stroke (NINCDS) perinatal study, 9
NEPSY – Second Edition (NEPSY-II), 216
NET selective reuptake blockers
effects on prefrontal cortical function, 165–7
neurobiology of ADHD, 123–4
neurobiology of learning disorders, 124
neurocognitive disorders, 155
neurodevelopmental disorders
differential diagnosis for ADHD, 151
neurofeedback, 311, 313–14
neurofibromatosis, 155
neurogenetic disorders
differential diagnosis of ADHD, 155–6
Neuroimaging Informatics Tools and Resources Clearinghouse, 205
neuroimaging of ADHD
ADHD-200 sample and Global Competition, 205
BOLD technique, 201–2
default network interference hypothesis of ADHD, 203
development of imaging techniques, 198
diffusion-tensor imaging (DTI), 200–1
distinctive neural signatures for ADHD subtypes, 205
echo-planar imaging (EPI), 202
fMRI studies of attention, 203–4
fMRI studies of inhibition, 203–4
future research, 206
meta-analyses of fMRI studies, 202–4
meta-analysis of DTI studies, 201
pneumo-encephalograms (PEG), 5–6
regional differences in gray matter volumes, 200
region-of-interest quantification, 199
resting-state functional MRI (R-fMRI) studies, 204–5
structural MRI studies, 198–201
task-based functional MRI (fMRI) studies, 201–4
total cerebral volume, 199–200
volumetric (morphometric) MRI studies, 198–9
voxel-based morphometry, 199–200
neuroimaging studies
comorbid bipolar disorder and ADHD, 75–6
neuroleptics
use in tic disorders and ADHD, 349
use in Tourette syndrome and ADHD, 349
neuropsychological assessment
brain structural abnormalities in ADHD, 211
case study (ADHD and anxiety), 220
case study (ADHD and bipolar disorder of childhood), 219
case study (ADHD and NOT dyslexia), 219–20
case study (ADHD differential diagnosis), 219
case study (comorbid ADHD and LD), 218–19
classification of cognitive functions, 211
cognitive assessment in ADHD, 211
cognitive function assessment in ADHD and management, 210
executive and higher cortical functions, 212–13
executive functions in ADHD, 211
Full Scale Intelligence Quotient (FSIQ), 211–12
genetic intellectual skills, 211–12
IQ (intelligence quotient), 211–12
language abilities, 213
lateralization of cognition in the brain, 211
learning assessment, 214
memory assessment, 214
perceptual skills, 213–14
role of the neuropsychologist, 210–11
sensorimotor skills, 214–15
visual-spatial skills, 213–14
neuropsychological tests
academic testing, 218
emotional function, 217–18
exaggerated presentations by examinees, 218
executive, attention, and "frontal" tests, 215–16
IQ tests, 215
language tests, 216
learning assessment, 217
memory assessment, 217
motor skills assessment, 217
secondary gain motives in examinees, 218
sensory functions assessment, 217
visual, spatial, and perceptual functions, 216–17
Wechsler intelligence tests, 215
neuroscience
contribution to ADHD research, 10
neurotransmitter-3 (NTF-3) ADHD association studies, 180
nicotine
effects on ADHD symptoms, 333
effects on attentional performance, 333
effects on behavioral inhibition, 333
nicotine dependence among smokers, 328
nicotinic agents, 289
nitric oxide synthase (NOSI) ADHD association studies, 183
non-stimulant medications
effects on prefrontal cortical function, 167–8
use in depressive disorders and ADHD, 89–90
use in ODD or CD with ADHD, 146
use in preschool ADHD, 323
non-stimulant treatment of ADHD
alpha-2 agonists, 263–5
amantadine, 267
atomoxetine, 261–3
buproprion, 265–6
buspirone, 266
clonidine, 263–5
guanfacine, 263–5
indications for use, 267–8
limitations of stimulant medications, 259–60
modafinil, 266–7
monoamine oxidase inhibitors (MAOIs), 267
neurobiological rationale, 260–1
range of non-stimulant medications, 261
tricyclic antidepressants (TCAs), 267
venlafaxine, 266
non-verbal learning disabilities (NVLD), 213
noradrenergic receptors (ADRA1A, A2A, 2C and 1C)
ADHD association studies, 179–80
norepinephrine
effects on prefrontal cortical function, 162–3
norepinephrine transporter (NET, SLC6A2)
ADHD association studies, 180
nortriptyline, 267
nutrition supplementation, 308–10
obesity
association with depression, 87
effects on ADHD symptoms in adults, 87
obcessive–compulsive disorder (OCD), 99
comorbidity with ADHD, 64
comorbidity with ADHD and tic disorders, 345
obstructive sleep apnea (OSA), 154
olanzapine, 147
omega-3 fatty acids, 349
oppositional defiant disorder (ODD), 4, 99
and somatoform disorders, 145
and substance use disorders (SUD), 145
association with ADHD and anxiety disorders, 102
biological factors in etiology, 141–2
biological risk factors for, 142
clinical assessment, 145–6
comorbid anxiety disorders, 144
comorbid mood disorders, 144–5
comorbidity, 144–5
comorbidity with ADHD, 18, 25, 26, 144
definition, 139–40
diagnostic criteria, 139–40
differential diagnosis (case study), 220
DSM-IV disruptive behavior disorders (DBD), 139
epidemiology, 140
etiology, 141–3
in preschool children, 318
overlap with reverse comorbidities, 64
pharmacological treatments, 146–7
potential for prevention, 143
prevalence, 140
prognosis, 143–4
psychological risk factors for, 142
psychopharmacological treatments, 147–8

pervasive developmental disorders
personality development
periodic limb movement disorder
perinatal neurological insults, 151
perinatal brain injury theories of disruptive behavior, 2–5, 6–7
Overt Aggression Scale, 145

parenting and ADHD, 49
parental psychopathology, 322
Parental Account of Symptoms (PACS), 183

Parental Health Questionnaire (PHQ), 8

Pediatric Anxiety Rating Scale (PARS), 104
pediatric bipolar disorder, 25
perceptual functions
neuropsychological tests, 216–17
Perceptual Reasoning Index (in WISC-IV), 126, 216
perceptual skills
neuropsychological assessment, 213–14
perinatal brain injury theories of behavioral problems, 7–9
perinatal neurological insults, 151
periodic limb movement disorder (PLMD), 154
personality development
effects of ADHD and depression, 87
pervasive developmental disorders (PDD) and ADHD
stimulant medications for pediatric use, 252–3

Peters, John, 7–8, 10

phakomatoses, 155
pharmacology of ADHD, 163–8
NET selective reuptake blockers, 165–7
non-stimulant medications, 165–8
noradrenergic α1 agonists, 167–8
psychostimulants, 163–5
pharmacotherapy in multimodal therapy, 10
influence of the FDA Modernization Act (1997), 12
pharmacotherapy of ADHD approach to use of medications, 276
drug–drug interactions, 282–3
pharmacotherapy of adult ADHD additional therapies, 276
alpha-adrenergic agonists, 289
amino acids, 289
ampakines, 289
antidepressants, 288–9
atomoxetine, 283–8
bupropion, 289
catecholamine-triamine reuptake inhibitors, 289
clonidine, 289
establishment of a diagnosis, 276
guanfacine, 289
modafinil, 289
monoamine oxidase inhibitors (MAOIs), 288–9
nicotinic agents, 289
prohistanergic agents, 289
setting treatment goals, 276
stimulants, 276–83
suggested management strategies, 289–90
treatment of refractory patients, 290–1
tricyclic antidepressants (TCAs), 288
pharmacokinetics of stimulant medications, 247
Phelps, Michael, 46
phenobarbital, 248
phenotype of ADHD heterogeneity, 12
phenoxytoin, 248
phobic disorders, 99
physician behavior
influence on treatment adherence, 357–8
pimozide, 349
Pittsburgh Side Effects Scale, 237
pneumo-encephalograms (PEG), 5–6
postinjury-emission tomography, 198
post-traumatic stress disorder (PTSD), 99
pramipexole, 349
predominantly hyperactive subtype of ADHD (DSM-IV), 16
predominantly inattentive subtype of ADHD (DSM-IV), 16
prefrontal cortex
catecholamine dysregulation in ADHD, 162
effects of atomoxetine, 165–7
effects of dopamine, 162–3
effects of genetic insults related to ADHD, 162
effects of methylphenidate, 161
effects of NET selective reuptake blockers, 165–7
effects of non-stimulant medications, 165–8
effects of noradrenergic α1 agonists, 167–8
effects of norepinephrine, 162–3
effects of pharmacological treatments for ADHD, 163–8
effects of psychostimulants, 163–5
functional deficits in ADHD, 213–14
regulation of attention, 161–2
regulation of behavior, 161–2
regulation of emotion, 161–2
requirement for optimal catecholamine levels, 162–3
role of catecholamines, 161
structure and function in ADHD patients, 162
preschool ADHD assessment issues, 239–40
behavioral interventions, 321–2
diagnosis/assessment, 319
effective interventions, 353
epidemiology, 318–19
evidence from PATS, 353
parent-training interventions, 321–2
pharmacotherapy, 322–3
pharmacotherapy considerations, 318
treatment guidelines, 321
Preschool ADHD Treatment Study (PATS), 319–21, 322, 353
Preschool Age Psychiatric Assessment (PAPA), 319
prevalence of ADHD in adults, 16, 27–9, 83–4
in children, 16, 24–5
primidone, 248
Processing Speed Index (in WISC-IV), 126
progressive ratio task, 334
prohistanergic agents, 289
proton magnetic resonance spectroscopic (1HMRS) imaging, 75–6
Provigil, 266
pseudoephedrine, 282

oppositional defiant disorder (ODD) (cont.)
risk factors for, 141–3
sociological factors in development, 142
stability of diagnosis, 143–4
treatment programs, 146–8
organic drivenness concept, 7
OROS MPH (osmotic-release oral system methylphenidate), 245
overstimulation theories of disruptive behavior, 2–5, 6–7
Oxidative Stress Scale, 87

Pittsburgh Side Effects Scale, 237
Pittsburgh Sleep Quality Index (PSQI), 226
plasma levels, 237

Pittsburgh Sleep Quality Index (PSQI), 226
plasma levels, 237

Pittsburgh Side Effects Scale, 237
Pittsburgh Sleep Quality Index (PSQI), 226
plasma levels, 237

Pittsburgh Side Effects Scale, 237
Pittsburgh Sleep Quality Index (PSQI), 226
plasma levels, 237

Pittsburgh Side Effects Scale, 237
Pittsburgh Sleep Quality Index (PSQI), 226
plasma levels, 237
psychiatric disorders  
comorbidity with ADHD in children, 18  
comorbidity with adult ADHD, 31–2  

psychiatric disorders in ADHD  
protective potential of stimulant treatment, 253–4  

psychopharmacology of ADHD  
discovery of effects of stimulant drugs, 5–6  
early history, 5–7  

psychosis  
associated with stimulant medications, 251  

psychosocial treatment of adult ADHD  
features of adult ADHD, 298  
future directions, 303–4  
limitation of stimulant medications in adults, 298  
Mount Sinai CBT program for adult ADHD, 300–4  
treatment literature before 2010, 298–300  
psychosocial treatments  
for college students with ADHD, 373–4  
for comorbid depression and ADHD, 91–2  

psychostimulants  
effect on prefrontal cortical function, 163–5  
Pycnogenol, 310, 313  
quality of life and ADHD, 49  
assessment scales, 229–30  
concept, 42  
quetiapine, 147  
Rafalovich, A., 1, 4–5  
Rapaport, Judith, 10  
rating scales for ADHD  
assessment issues in adolescents, 238–9  
assessment issues in preschool children, 239–40  
choice of, 236  
description and use, 234–5  
for functional impairment, 236–7  
function, 233–4  
history, 233–4  
recommendations for clinical use, 240  
to aid diagnosis of ADHD in children, 19  
to assess treatment response in adults, 276  
to track adverse events, 237–8  
to track side effects, 237–8  
See also diagnostic scales; symptom rating scales  
reading disorder  
differential diagnosis case study, 219–20  
DSM-IV criteria, 125  
reading disorder and ADHD, 127  
early diagnosis, 217–30  
nuerobiology of reading disorders, 124  
recurrent brief depression (RBD) and ADHD, 85  
region-of-interest quantification neuroimaging of ADHD, 199  
Relational Frame Theory, 355, 356  
approach to ADHD treatment, 359–60  
relaxation therapies, 311  
resistance to thyroid hormone and ADHD, 157  
restless legs syndrome (RLS), 154, 155  
Rey–Osterreith Complex Figure (ROCF) test, 217  
rheumatoid arthritis, 158  
risperidone, 76, 147, 349  
Ritalin LA, 323  
Rutter, M., 9  
Safer, D. J., 10  
Schedule for Affective Disorders and Schizophrenia (SADS), 218  
Schedule for Affective Disorders and Schizophrenia for School Age Children (K-SADS), 183, 238  
seasonal affective disorder (SAD) and ADHD in adults, 85  
seizure disorders  
differential diagnosis of ADHD, 152–4  
seizure disorders and ADHD  
stimulant medications for pediatric use, 253  
selective serotonin reuptake inhibitors (SSRIs), 90–1, 147, 165  
selegiline, 90, 267, 288  
self-control  
and treatment adherence, 355–7  
sensorimotor skills  
neuropsychological assessment, 214–15  
sensory deficits  
differential diagnosis for ADHD, 152  
sensory functions  
neuropsychological tests, 217  
separation anxiety disorder in children, 99  
serotonergic genes  
ADHD association studies, 180–2  
serotonin receptor (HTR1B)  
ADHD association studies, 180–1  
serotonin receptor (HTR2A, 5HT2A)  
ADHD association studies, 181  
serotonin receptor (HTR2C)  
ADHD association studies, 181  
serotonin transporter (HTT, SLC6A4)  
ADHD association studies, 181  
severe mood dysregulation (SMD) phenotype, 66  
SF-36 measure, 42  
Side Effect Rating Scale (SERS), 237  
side effects  
rating scales to track, 237–8  
Skinner, B. F., 355  
sleep apnea, 155  
sleep disorders  
differential diagnosis of ADHD, 154–5  
sleep problems, 49  
smoking  
morbidity and mortality caused by, 327  
rates among individuals with psychiatric disorders, 327  
smoking and ADHD  
ADHD as risk factor for smoking, 112–13, 327–8  
behavioral mechanisms, 333  
clinical implications, 333–4  
common genetic substrates, 330–1  
consequences of smoking during pregnancy, 143  
effects of ADHD treatment, 112  
effects of maternal smoking, 346  
effects of nicotine on ADHD symptoms, 333  
effects of nicotine on attentional performance, 333  
effects of nicotine on behavioral inhibition, 333  
effects of stimulant medications, 333–4  
evidence for association, 327  
genetic substrates of smoking and ADHD, 330–1  
influence of ADHD on the stages of smoking, 328–30  
inTEGRATED model of ADHD–smoking comorbidity, 334–5  
neurobiological/neuropsychological factors, 332  
nicotine dependence among smokers, 328  
prevalence, 328
Index

smoking and ADHD (cont.) prevention implications, 335–6 self-medication hypotheses, 333 treatment implications, 335–6 SNAP-IV, 84, 347
Social Adjustment Inventory for Children and Adolescents (SAICA), 237
Social and Occupational Functioning Assessment Scale, 59
Social Communication Questionnaire, 68
social functioning impairment in ADHD, 47–9
social phobia, 99
sociodemographic correlates with adult ADHD, 32–3 socioeconomic status adults with ADHD, 33 somatoform disorders comorbidity with ODD and CD, 145 spatial functions neuropsychological tests, 216–17 specific learning disability, 7–8 specific learning disorder, 6
Spitzer, Robert, 9
St. John’s Wort, 310
Still, George F., 4–5, 16
stimulant drugs discovery of effects on behavior-disordered children, 5–6 stimulant medication limitations abuse potential, 260 cardiovascular effects, 260 effects on growth, 259–60 indications for non-stimulant use, 267–8
side effects, 259
tic disorders, 260 tolerability, 259
treatment response, 259
stimulant medications adverse effects in adults, 281–2 cognition-enhancing effects in normal subjects, 164–5 drug–drug interactions, 282–3 effects on prefrontal cortical function, 163–5
effects on smoking and ADHD, 333–4
issues for college students with ADHD, 371–3 limitations in adult ADHD, 259, 298
misuse and diversion issues, 118 risk of substance use disorders, 112 side effects in adults, 281–2
use in adult ADHD, 276–83
use in depressive disorders and ADHD, 89
use in ODD or CD with ADHD, 146
use in preschool ADHD, 322–3
use in tic disorders and ADHD, 348
use in Tourette syndrome and ADHD, 348
stimulant medications for pediatric use ADHD with comorbid conditions, 252–3
amphetamine preparations, 245, 246–7
approach to pharmacotherapy, 254
carcinogenic effects, 250–2
common/expected adverse effects, 249–50
comorbid bipolar disorder and ADHD, 252
comorbid pervasive developmental disorders (PDD) and ADHD, 252–3
comorbid seizure disorders and ADHD, 253
dosing and administration, 247–8
drug efficacy, 248–9
drug safety, 248–9
effects on tic disorders, 250
height and weight changes, 250
issues of misuse and diversion, 252
long-term/unexpected adverse effects, 250–2
medication holidays, 248
medication interruptions, 248
methylphenidate preparations, 245–6
mood dysregulation associated with, 251
pharmacokinetics, 247
potential drug–drug interactions, 248
potential protection against psychiatric disorder development, 253–4
psychosis associated with, 251
risk of cardiac complications, 250–1
risk of substance abuse, 252
risk of sudden death, 250–1
treatment-emergent tics, 250
Stop Signal task, 67, 162
Strattera®, 89, 262–3
use in tic disorders and ADHD, 348
use in Tourette syndrome and ADHD, 348
Stroop Color and Word Test, 216
Stroop-type tests, 216
Structured Clinical Interview for DSM (SCID), 72, 73
Structured Clinical Interview for DSM-IV-TR Axis I Disorders (SCID-I), 227
Sturge–Weber syndrome, 155
substance-prefering receptor (Tacr1)
ADHD association studies, 183
substance use disorders (SUD) abuse potential of stimulant medications, 260
and conduct disorder (CD), 145
and oppositional defiant disorder (ODD), 145
differential diagnosis, 152
risk related to stimulant treatment, 252
substance use disorders (SUD) and ADHD
ADHD as a risk factor for SUD, 111–12
ADHD as risk factor for smoking, 112–13
ADHD treatment and later SUD, 112
diagnosis, 113
future research, 118–19
misuse and diversion of prescribed stimulants, 118
onset and prevalence of each, 111
overlap between, 111
prevalence of comorbidity, 111
self-medication hypothesis, 113
SUD pathways associated with ADHD, 112–13
treatment guidelines, 113–18
subtypes of ADHD, 16
clinical relevance, 59–60
diagnostic criteria, 17
distinctive neural signatures, 205
in adults, 20
prevalence of anxiety disorders, 102
sudden death risk and use of stimulant medications, 250–1
suicidality risk with antidepressants, 147
suicide risk in adults with ADHD and depression, 87
Supplemental Security Income Program, 12
Sustained Attention to Response Task, 178
Sutter–Eyberg Student Behavior Inventory – Revised, 145
Swanson, Kotkin, Agler, M-Flynn, and Pelham Scale (SKAMP), 19, 237
Swanson, Nolan, and Pelham IV Questionnaire (SNAP-IV), 19
Swanson, Nolan, Pelham IV Teacher and Parent Rating Scales (SNAP-IV), 234
Sydenham’s chorea
differential diagnosis of ADHD, 154
symptom assessment scales for adult ADHD, 228–9
Symptom Checklist 90-Revised, 65
symptom ratingscales use in adult ADHD, 224
See also diagnostic scales; rating scales
symptoms concept, 42
synaptosomal associated protein (SNAP-25)
ADHD association studies, 182
Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD), 73, 86
Teacher Report Form (of the CBCL), 145, 234
temper dysregulation disorder (TDD), 6, 66–7
Test of Variablesof Attention (TOVA), 215
Test of Word Reading Efficiency (TOWRE), 218
The Lancet, 4
thyroid disorders
differential diagnosis of ADHD, 156–7
tic disorders
clonic tics, 343
comorbidity with ADHD, 64
complex motor tics, 343–4
complex vocal tics, 343
coprolalia, 343
copropraxia, 343
definitions and features, 343–4
differential diagnosis of ADHD, 154
dystonic tics, 343
echolalia, 343
echopraxia, 343
effects of stimulant medications, 250, 260
"just right" phenomena, 344
palilalia, 343
premonitory sensations, 344
prevalence, 344
simple motor tics, 343
simple vocal tics, 343
tonic tics, 343
treatment-emergent tics, 250
tic disorders and ADHD
alpha-adrenergic agonist medications, 348
behavior therapy for tics, 349
bidirectional overlap, 343
clinical phenomenology, 344–5
comorbidity with OCD, 345
diagnostic criteria for tic disorders, 344
epidemiology, 344–5
evaluation, 347
genetic factors in tic disorders, 347
pathophysiology, 345–7
pharmacotherapy, 347–9
prevalence of comorbidity, 343, 345
stimulant medications, 348
treatment, 347–9
treatment approach, 343
use of atomoxetine, 348
use of neuroleptics, 349
use of tricyclic antidepressants (TCAs), 348–9
time, sense of, 49
total cerebral volume
neuroimaging of ADHD, 199–200
Tourette syndrome
differential diagnosis for ADHD, 154
premonitory sensations, 344
prevalence, 344
Tourette syndrome and ADHD
alpha-adrenergic agonist medications, 348
behavior therapy for tics, 349
bidirectional overlap, 343
clinical phenomenology, 344–5
comorbidity with OCD, 345
definitions and features of tic disorders, 343–4
diagnostic criteria for tic disorders, 344
epidemiology, 344–5
etiology, 345–7
evaluation, 347
genetic factors in tic disorders, 347
pathophysiology, 345–7
pharmacotherapy, 347–9
prevalence of comorbidity, 343, 345
stimulant medications, 348
treatment, 347–9
treatment approach, 343
use of atomoxetine, 348
use of neuroleptics, 349
use of tricyclic antidepressants (TCAs), 348–9
time, sense of, 49
total cerebral volume
neuroimaging of ADHD, 199–200
Tourette Syndrome Association, 347
Tourette Syndrome Association International Consortium for Genetics (TSAICG), 347
Tower of Hanoi test, 216
Tower of London test, 216
Tract Based Spatial Statistics (TBSS), 201
Trail Making Tests, 215
tranylcypromine, 267
treatment adherence impact (TAI) measure, 362
treatment adherence in ADHD
adherence approach in WHO short course tuberculosis program, 357
direct observation therapy (DOT), 357
easing logistics of treatment, 359–60
effective medical interventions, 353–4
explaining treatment adherence, 355–7
extent of non-adherence, 354–5
influence of language on behavior, 355–6
influence of physician behavior, 357–8
interventions for adolescent ADHD, 354
interventions for adult ADHD, 354
interventions for preschool children, 353
interventions for school-age children, 354
lessons learned from ADHD, 358–9
lessons learned from other chronic conditions, 357–8
moderators and mediators, 357–8
multicomponent adherence interventions, 358
ongoing monitoring of treatment, 358
patients as participant-collaborators, 361–2
potential impacts of untreated ADHD, 353
psychosocial interventions, 354
Relational Frame Theory, 356
replacing rule-governed behavior with valued behavior, 356–7
self-control concept, 355–7
strategies to promote adherence, 359–61
strengthening valued behavior, 359–61
transforming rules, 359–61
treatment adherence impact (TAI) measure, 362
triadic model of intervention, 356–7
Treatment for Adolescents with Depression Study (TADS), 89, 354
Treatment for Adults with ADHD adult ADHD, 33
multimodal therapy, 10
potential benefits of early treatment, 34
See also specific treatments
Tredgold, A. F., 7
triadic model of intervention, 356–7
Index

tricyclic antidepressants (TCAs), 90, 147
drug–drug interactions, 248, 283
use in ADHD treatment, 267
use in adult ADHD, 288
use in tic disorders and ADHD, 348–9
use in Tourette syndrome and ADHD, 348–9
trypotphan hydroxylase (TPH and TPH2)
ADHD association studies, 181–2
tuberous sclerosis, 155
Turner syndrome, 152
Twain, Mark, 3
valerian, 310
valproate semisodium, 147
Vanderbilt ADHD Diagnostic Parent/
Teacher Rating Scales, 234, 236
vasopressor drugs, 248
velo-cardio-facial syndrome (VCFS), 152
venlafaxine, 90–1, 261, 266
Verbal Comprehension Index (in
WISC-IV), 126, 216
vestibular stimulation, 312
Vineland Scales of Adaptive Behavior, 237
visual functions
everropsychological tests, 216–17
visual-spatial skills
neuropsychological assessment, 213–14
vitamin supplementation, 309
von Economo's encephalitis, 5–6
voxel-based morphometry studies in
ADHD, 199–200
Vyanse®, 89, 93, 372
Wechsler Adult Intelligence Scale –
Fourth Edition (WAIS-IV), 126
Wechsler Individual Achievement
Test – Third Edition (WIAT-III),
126, 218
Wechsler Intelligence Scale for
Children – Fourth Edition
(WISC-IV), 126, 216
Wechsler Intelligence tests, 215
language tests, 216
tests of visual and spatial abilities, 216
Wechsler Memory Scale – Fourth
Edition (WMS-IV), 217
weight
effects of stimulant medications, 250
Weiss Functional Impairment Rating
Scale, 42, 45, 237
Weiss Functional Impairment Rating
Scale Self-Report (WFIRS-S), 230
Wellbutrin, 93
Wender–Reimherr Adult ADHD
Rating Scale, 276
Wender, P., 8, 10
Wender–Reimherr Adult Attention
Deficit Disorder Scale
(WRAADDS), 229
WHO Disability Assessment Schedule, 32
WHO Disability Assessment Schedule
2 (WHODAS 2), 42
WHO short course in tuberculosis
treatment, 357
Wide Range Assessment of Memory of
Learning – Second Edition
(WRAML2), 217
Williams syndrome, 152
Wisconsin Card Sorting Test (WCST),
216
Woodcock–Johnson Tests of Academic
Achievement, Third Edition
(WJ-III), 126, 218
work environment
and functional impairment in
ADHD, 46–7
work performance
adults with ADHD, 20
Working Memory Index (in
WISC-IV), 126
working memory training, 311–12,
314
workplacescreening programs for
ADHD, 34
written expression disorder
and ADHD, 127
DSM-IV criteria, 126
Yale–Brown Obsessive Compulsive
Scale (YBOCS), 347
Yale Global Tic Severity Scale,
347
yoga, 312
Zeitgeist explanation for scientific
progress, 2–5
zinc supplements, 309
ziprasidone, 147, 349